drugset / Trial / NCT02118051

Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.

NCT02118051

Phase 3 Completed 234 enrolled La Fe Health Research Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

Patients who have had or are expected to have a poor ovarian response (POR), because they meet any of the criteria of Bologna, can benefit from ovarian stimulation with 150 mg of alpha Corifollitropin (CFA) (Elonva ®) as single dose for a week, in the cycles of in vitro fertilization (IVF). In this study aims to demonstrate non-inferiority of the Corifollitropin Alpha (CFA ) versus daily administration of Human Menopausal Gonadotropin (hMG) (Menopur ®) during the first seven days of ovarian stimulation, in a protocol with gonadotropin-releasing hormone ( GnRH) antagonists

Timeline

Start
2013-09
Primary completion
2017-06
Completion
2017-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Ganirelix Protein / enzyme biologic 250 ug Subcutaneous
Background Ovidrel Protein / enzyme biologic 6500 iu
Background Progesterone Other / unclassified 400 mg Intravenous

Indications